Creatine in 2026 — what the new research actually says (and why it matters more for women than most people think)
Been going deep on creatine research this week and wanted to share a few things that genuinely surprised me — even as an RD who already recommends it. Three highlights from papers published in the last 6 weeks: 1. It works on your brain, not just your muscles A placebo-controlled study published in April 2026 (Nutrients) had people go 21 hours without sleep, then tested cognitive performance after a single creatine dose. The creatine group scored ~12% better. Women specifically outperformed on logic and language tasks. Not a typical use case, but it tells us something important about why creatine works: your brain runs on phosphocreatine the same way your muscles do. This isn't a gym supplement. It's an energy substrate. 2. The cognitive research in older adults is getting serious The CABA trial — a 240-participant multicenter RCT published May 2026 — found 5 g/day of creatine monohydrate slowed cognitive decline in early Alzheimer's patients by roughly 30% over 12 weeks. MRI confirmed increased brain phosphocreatine. One trial doesn't change everything, but combined with the growing cognition literature, it's hard to keep calling this a "bodybuilding supplement." 3. Postmenopausal women show some of the strongest responses Network meta-analysis (Nutrients, June 2026) confirms creatine is the single most consistent intervention for strength outcomes — and the CONCRET-MENOPA trial specifically found that creatine + resistance training outperforms training alone in postmenopausal women. Practical bottom line: - Form: creatine monohydrate - Dose: 3–5 g/day - No loading phase required (full saturation in ~4 weeks) - Best results with consistent resistance training